On Thursday, a Federal Circuit panel posed doubts over whether a patent covering Allergan’s bowel treatment drug, Viberzi, should have its life abbreviated based on the expiration date of kindred patents. This line of questioning occurred during oral arguments concerning obviousness-type double patenting. As such, it has raised questions on whether Allergan may have illegally stretched its exclusivity.
While these debates currently focus on Allergan’s drug Viberzi, the implications of this case could further reach, affecting how pharmaceutical companies manage the life cycle of their patent protections.
For detailed background and further updates on this case, legal professionals might wish to peruse the original court proceedings. Keeping abreast of the situation as it unfolds could provide invaluable insights for those involved in pharmaceutical law, intellectual property, and patent law.